A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04583995 |
|
Recruitment Status :
Completed
First Posted : October 12, 2020
Last Update Posted : April 10, 2023
|
Sponsor:
Novavax
Information provided by (Responsible Party):
Novavax
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is a study to evaluate the efficacy, immune response, and safety of a coronavirus disease 2019 (COVID-19) vaccine called SARS-CoV-2 rS with Matrix-M1 adjuvant in adults aged 18-84 years in the United Kingdom. A vaccine causes the body to have an immune response that may help prevent the infection or reduce the severity of symptoms. An adjuvant is something that can make a vaccine work better. This study will look at the protective effect, body's immune response, and safety of SARS-CoV-2 rS with Matrix-M1 adjuvant in the study population. Participants in the study will randomly be assigned to receive SARS-CoV-2 rS with Matrix-M1 adjuvant or placebo. Each participant in the study will receive a total of 2 intramuscular injections over the course of the study. Approximately 15,000 participants will take part in the study. The first approximately 400 participants who meet additional criteria will receive a flu vaccine, in addition to the SARS-CoV-2 rS vaccine or placebo, as part of a sub-study.
An effort will be made to enroll a target of at least 25% of participants who are ≥ 65 years of age, as well as prioritizing other groups that are most affected by COVID-19, including racial and ethnic minorities.
Unblinding of treatment assignment may occur in order to allow a participant to make an informed decision regarding receipt of an already approved or deployed SARS-CoV-2 vaccine. Participants who choose to receive an approved or deployed SARS-CoV-2 vaccine as per UK government guidance will be encouraged to remain in the study for scheduled safety assessments.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| SARS-CoV-2 Infection COVID-19 | Biological: SARS-CoV-2 rS/Matrix M1-Adjuvant Other: Placebo Biological: Licensed seasonal influenza vaccine | Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 15138 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Prevention |
| Official Title: | A Phase 3, Randomised, Observer-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in Adult Participants 18-84 Years of Age in the United Kingdom |
| Actual Study Start Date : | September 28, 2020 |
| Actual Primary Completion Date : | March 29, 2022 |
| Actual Study Completion Date : | March 29, 2022 |
Resource links provided by the National Library of Medicine
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Cohort 1: SARS-CoV-2 rS/Matrix-M1 Adjuvant
2 doses of 5 µg SARS-CoV-2 rS + 50 µg Matrix-M1 adjuvant (co-formulated), 1 dose each on Days 0 and 21.
|
Biological: SARS-CoV-2 rS/Matrix M1-Adjuvant
Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Days 0 and 21.
Other Name: NVX-CoV2373 |
|
Placebo Comparator: Cohort 1: Placebo
2 doses of Placebo (Saline), 1 dose each on Days 0 and 21.
|
Other: Placebo
Alternating intramuscular (deltoid) injections of placebo (0.5 mL) on Days 0 and 21.
Other Name: Sodium chloride 0.9% (BP, sterile) |
|
Experimental: Cohort 2: SARS-CoV-2 rS/Matrix-M1 Adjuvant Plus Licensed Seasonal Flu Vaccine
2 doses of 5 µg SARS-CoV-2 rS + 50 µg Matrix-M1 adjuvant (co-formulated), 1 dose each on Days 0 and 21. 1 dose of licensed seasonal flu vaccine on Day 0.
|
Biological: SARS-CoV-2 rS/Matrix M1-Adjuvant
Alternating intramuscular (deltoid) injections of SARS-CoV-2 rS co-formulated with Matrix-M1 adjuvant (0.5 mL) on Days 0 and 21.
Other Name: NVX-CoV2373 Biological: Licensed seasonal influenza vaccine Single intramuscular injection of licensed seasonal flu vaccine, administered ideally in opposite deltoid to SARS-CoV-2 rS with Matrix-M1 adjuvant or placebo injection on Day 0. |
|
Placebo Comparator: Cohort 2: Placebo Plus Licensed Seasonal Flu Vaccine
2 doses of Placebo (Saline), 1 dose each on Days 0 and 21. 1 dose of licensed seasonal flu vaccine on Day 0.
|
Other: Placebo
Alternating intramuscular (deltoid) injections of placebo (0.5 mL) on Days 0 and 21.
Other Name: Sodium chloride 0.9% (BP, sterile) Biological: Licensed seasonal influenza vaccine Single intramuscular injection of licensed seasonal flu vaccine, administered ideally in opposite deltoid to SARS-CoV-2 rS with Matrix-M1 adjuvant or placebo injection on Day 0. |
Primary Outcome Measures :
- Participants with Symptomatic Mild, Moderate, or Severe Coronavirus Disease 2019 (COVID-19) [ Time Frame: From Day 28 to Day 386 ]Number of participants, testing serologically negative for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at baseline, with first occurrence of positive (+) polymerase chain reaction (PCR)-confirmed SARS-CoV-2 illness with symptomatic mild, moderate, or severe COVID-19 with onset from Day 28 through the length of the study.
Secondary Outcome Measures :
- Participants with Symptomatic Moderate or Severe COVID-19 [ Time Frame: From Day 28 to Day 386 ]Number of participants, testing serologically negative for SARS-CoV-2 at baseline with first occurrence of (+) PCR-confirmed, SARS-CoV-2 illness with symptomatic moderate or severe COVID-19 with onset from Day 28 through the length of the study.
- Participants with Symptomatic Severe COVID-19 [ Time Frame: From Day 28 to Day 386 ]Number of participants, testing serologically negative for SARS-CoV-2 at baseline with first occurrence of (+) PCR-confirmed, SARS-CoV-2 illness with symptomatic severe COVID-19 with onset from Day 28 through the length of the study.
- Participants with Symptomatic Mild, Moderate, or Severe COVID-19 Regardless of Baseline Serostatus [ Time Frame: From Day 28 to Day 386 ]Number of participants, regardless of serostatus at baseline, with first occurrence of (+) PCR-confirmed, SARS-CoV-2 illness with symptomatic mild, moderate, or severe COVID-19 assessed from Day 28 through the length of the study.
- Participants with Asymptomatic or Symptomatic COVID-19 [ Time Frame: From Day 28 to Day 386 ]Number of participants, regardless of serostatus at baseline, with first occurrence of (+) PCR-confirmed, or nucleocapsid protein serologically confirmed, SARS-CoV-2 illness with asymptomatic or symptomatic COVID-19 with onset from Day 28 through the length of the study.
- Participants with COVID-19 requiring Hospitalization, Intensive Care Unit (ICU), or Mechanical Ventilation [ Time Frame: From Day 28 to Day 386 ]Number of participants, regardless of serostatus at baseline, with first occurrence of (+) PCR-confirmed, SARS-CoV-2 illness with COVID-19 with onset from Day 28 through the length of the study.
- Participants with Symptomatic Mild COVID-19 [ Time Frame: From Day 28 to Day 386 ]Number of participants, regardless of serostatus at baseline, with first occurrence of (+) PCR-confirmed, SARS-CoV-2 illness with symptomatic mild COVID-19 (with no progression to moderate or severe COVID-19 during the course of the COVID-19 episode) with onset from Day 28 through the length of the study.
- Serum IgG Antibody Levels at Multiple Time Points Expressed as Geometric Mean ELISA Units (GMEUs) [ Time Frame: Day 0 to Day 35 ]Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by enzyme-linked immunosorbent assay (ELISA) expressed as GMEUs at Day 0 and Day 35.
- Participants with Serious Adverse Events (SAEs) [ Time Frame: 386 days ]Number of participants with SAEs through the length of the study by Medical Dictionary for Regulatory Activities (MedDRA) classification and relationship to study vaccination.
- Participants with Medically Attended Adverse Events (MAAEs) Related to Study Vaccination [ Time Frame: 386 days ]Number of participants with MAAEs related to study vaccination through the length of the study by MedDRA classification.
- Participants with Adverse Events of Special Interest (AESIs) [ Time Frame: 386 days ]Number of participants with AESIs, which include potential immune-mediated medical conditions (PIMMCs) and AESIs relevant to COVID-19 such as possible vaccine-enhanced disease by MedDRA classification through the length of the study.
- Participants with Solicited Local and Systemic Adverse Events (AEs) [ Time Frame: 28 days ]Number of participants with solicited local and systemic AEs for 7 days after each study vaccination.
- Participants with All MAAEs Through Day 35 [ Time Frame: 35 days ]Number of participants with all MAAEs through Day 35 by MedDRA classification and relationship to study vaccination.
- Participants with Unsolicited AEs Through Day 49 [ Time Frame: 49 days ]Number of participants with unsolicited AEs through Day 49 by MedDRA classification and relationship to study vaccination.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 84 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Able and willing to comply with all study requirements.
- Willing to allow investigators to discuss medical history with their General Practitioner and access all relevant medical records.
- Willing and able to give informed consent.
- Women of child-bearing potential must agree not to have sexual intercourse with men, or must consistently use an agreed method of contraception, from at least 28 days prior to enrolment in the study, through 3 months after the last vaccination.
- Room air oxygen saturation > 95% at Screening/Day 0.
- Seasonal Flu Vaccine Co-Administration Sub-Study only: Participant should not have received a current season flu vaccine, should have no reason why the specific sub-study flu vaccine cannot be administered, and should not have any prior history of allergy or severe reaction to seasonal flu vaccines.
Exclusion Criteria:
- Participation in other COVID-19 vaccine or preventative drug trials for the duration of the study.
- Future participation in any blood tests for the duration of the study where participants are informed of their levels of COVID-19 antibodies or antigens.
- Participation in any trial involving an investigational drug, biologic or device within 45 days prior to the first study vaccination.
- History of laboratory-confirmed COVID-19 infection any time prior to first study vaccination.
- Receipt of any immunoglobulins and/or any blood products within 3 months prior to planned administration of study vaccine.
- Any confirmed or suspected immunosuppressive or immunodeficient state. Chronic administration (defined as more than 14 continuous days) of immunosuppressant medication within the past 3 months, except topical steroids or short-term oral steroids (course lasting ≤ 14 days). Note: An immunosuppressant dose of glucocorticoid is defined as a systemic dose ≥ 10 mg of prednisone per day or equivalent. The use of topical, inhaled, and nasal glucocorticoids will be permitted if other chronic disease conditions do not exclude a participant from the study.
- History of allergic disease or reactions likely to be made worse by any component of the study vaccines.
- History of anaphylaxis to any prior vaccine.
- Pregnancy, breast-feeding or willingness/intention to become pregnant within 3 months following the last study vaccination.
- Current diagnosis of or treatment for cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ.
- Bleeding disorder, or prior history of significant bleeding or bruising following intramuscular injections or venepuncture (e.g. to draw blood for tests).
- Continuous use of anticoagulants or anti-platelet agents. Note: The preventative use of ≤ 325 mg of aspirin per day is permitted.
- Suspected or known current alcohol or drug dependency.
- Study team member or first-degree relative of any study team member (inclusive of sponsor, contract research organization (CRO), and site personnel involved in the study).
- Participants having any current workup of undiagnosed illness within 8 weeks prior to start of study which could lead to new condition or diagnosis.
- Received any live vaccine within 4 weeks or any vaccine (excluding flu) within 2 weeks prior to first study vaccination; or any licensed flu vaccine within 1 week prior to first study vaccination or plans to receive any vaccine from these time periods until 28 days after the second study vaccination.
- Have clinically significant chronic cardiovascular, endocrine (hormones), gastrointestinal, hepatic (including hepatitis B and C), renal (kidney), neurological, respiratory, psychiatric or other medical disorders not excluded by other exclusion criteria, that are assessed by the investigator as being clinically unstable within the prior 4 weeks as evidenced by: a) Hospitalisation for the condition, including day surgical interventions; b) New significant organ function deterioration; or c) Needing addition of new treatments or major dose adjustments of current treatments (mild or moderate well-controlled comorbidities are allowed).
- History of chronic neurological disorders that have required prior specialist physician review for diagnosis and management (such as multiple sclerosis, dementia, transient ischemic attacks, Parkinson's disease, degenerative neurological conditions, and neuropathy) or a history of stroke or previous neurological disorder within 12 months with residual symptoms. Participants with a history of migraine or chronic headaches or nerve root compression that have been stable on treatment for the last 4 weeks are not excluded.
- Any autoimmune disease/condition (iatrogenic or congenital).
- Any other significant disease, disorder or finding that, in the opinion of the investigator, may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study, or impair interpretation of the study data.
- Participant requires the use of continuous oxygen therapy or any oxygen therapy while awake or is anticipated to require daytime oxygen therapy during the course of the study.
Other protocol-defined inclusion/exclusion criteria may apply.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04583995
Locations
Show 33 study locations
Sponsors and Collaborators
Novavax
Investigators
| Study Director: | Clinical Development | Novavax, Inc. | |
| Principal Investigator: | Paul T Heath, MB BS FRACP FRCPCH | Vaccine Institute, St Georges, University of London |
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Novavax |
| ClinicalTrials.gov Identifier: | NCT04583995 |
| Other Study ID Numbers: |
2019nCoV-302 |
| First Posted: | October 12, 2020 Key Record Dates |
| Last Update Posted: | April 10, 2023 |
| Last Verified: | April 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
| Product Manufactured in and Exported from the U.S.: | Yes |
Keywords provided by Novavax:
|
Coronavirus |
Additional relevant MeSH terms:
|
COVID-19 Pneumonia, Viral Pneumonia Respiratory Tract Infections Infections Virus Diseases |
Coronavirus Infections Coronaviridae Infections Nidovirales Infections RNA Virus Infections Lung Diseases Respiratory Tract Diseases |